Treatment burden in stage i seminoma: A comparison of surveillance and adjuvant radiation therapy

BJU International

Volumn 112, Issue 8, 2013, Pages 1088-1095

  Leung, Eric ^a,c   Warde, Padraig ^a,c   Jewett, Michael ^a,c   Panzarella, Tony ^a,c   O'Malley, Martin ^a,c   Sweet, Joan ^b,c   Moore, Malcolm ^a,c   Sturgeon, Jeremy ^d   Gospodarowicz, Mary ^a,c   Chung, Peter ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

burden; radiation; seminoma; stage 1; surveillance; treatment

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; TUMOR MARKER; VINBLASTINE;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISTANT METASTASIS; EVALUATION AND FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; SALVAGE THERAPY; SEMINOMA; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

BURDEN; RADIATION; SEMINOMA; STAGE 1; SURVEILLANCE; TREATMENT;

CHEMOTHERAPY, ADJUVANT; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORCHIECTOMY; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN; WATCHFUL WAITING;

EID: 84887319824     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12330     Document Type: Article

References (34)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 17: 2893-2917
2. Chia V, Quraishi S, Devesa S, et al. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev 2010; 19: 1151-1159
3. Chung P, Mayhew LA, Warde P, Winquist E, Lukka H,. Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol) 2010; 22: 6-16
4. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer.[see comment]. J Natl Cancer Inst 1997; 89: 1429-1439
5. Daugaard G, Petersen PM, Rorth M,. Surveillance in stage I testicular cancer. Apmis. 2003; 111: 76-83; discussion 5
6. Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995 13: 2255-2262
7. Warde PR, Gospodarowicz MK, Goodman PJ, et al. Results of a policy of surveillance in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 1993; 27: 11-15
8. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008; 53: 478-496
9. Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw 2009; 7: 672-693
10. Wood L, Kollmannsberger C, Jewett M, et al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J. 2010; 4: e19-38
11. Cummins S, Yau T, Huddart R, Dearnaley D, Horwich A,. Surveillance in stage I seminoma patients: a long-term assessment. Eur Urol 2010; 57: 673-678
12. Oliver RT,. Limitations to the use of surveillance as an option in the management of stage I seminoma. Int J Androl 1987; 10: 263-268
13. Oliver RT, Edmonds PM, Ong JY, et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys 1994; 29: 3-8
14. Tolan S, Vesprini D, Jewett MA, et al. No role for routine chest radiography in stage I seminoma surveillance. Eur Urol 2010; 57: 474-479
15. Vesprini D, Chung P, Tolan S, et al. Utility of serum tumor markers during surveillance for stage I seminoma. Cancer [Evaluation Studies]. 2012; 118: 5245-5250
16. Horwich A, Alsanjari N, A'Hern R, et al. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 1992; 65: 775-778
17. von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 1993; 29A: 1931-1934
18. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 1999; 17: 1146-1154
19. Germa-Lluch JR, Garcia del Muro X, Maroto P, et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 2002; 42: 553-562; discussion 62-3
20. Ramakrishnan S, Champion AE, Dorreen MS, Fox M,. Stage I seminoma of the testis: is post-orchidectomy surveillance a safe alternative to routine postoperative radiotherapy? Clin Oncol (R Coll Radiol) 1992; 4: 284-286
21. Hoffman KE, Chen MH, Punglia RS, Beard CJ, D'Amico AV,. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol 2008; 26: 3937-3942
22. Nattinger AB, Hoffman RG, Shapiro R, Gottlieb MS, Goodwin JS,. The effect of legislative requirements on the use of breast-conserving surgery. N Engl J Med 1996; 335: 1035-1040
23. Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 2011; 29: 957-962
24. Tandstad T, Smaaland R, Solberg A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol 2011; 29: 719-725
25. Chung PW, Warde PR, Panzarella T, et al. Appropriate radiation volume for stage IIA/B testicular seminoma. Int J Radiat Oncol Biol Phys 2003; 56: 746-748
26. Classen J, Schmidberger H, Meisner C, et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003; 21: 1101-1106
27. Vallis KA, Howard GC, Duncan W, Cornbleet MA, Kerr GR,. Radiotherapy for stages I and II testicular seminoma: results and morbidity in 238 patients. Br J Radiol 1995; 68: 400-405
28. Zagars GK, Pollack A,. Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys 2001; 51: 643-649
29. Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989-1996
30. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97: 1354-1365
31. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.[see comment]. J Clin Oncol 2007; 25: 4370-4378
32. Schaapveld M, van den Belt-Dusebout AW, Gietema JA, et al. Risk and prognostic significance of metachronous contralateral testicular germ cell tumours. Br J Cancer 2012; 107: 1637-1643
33. Cox J,. Cost analysis of adjuvant management strategies in early-stage testicular seminoma. Genitourin Cancer Symp Proc 2013
34. Sridharan S, Chung P, Warde P,. The Management of Relapsed Stage I Seminoma. Genitourin Cancer Symp Proc 2013